而在姜利民离职后，广东分公司总经理职务将由刘兴科补位。刘兴科自加入友邦以来，深度参与了友邦 人士区域拓展的前线工作，曾担任友邦人寿首席执行官特别助理并负责新市场和新机构的各项开拓工 作，任职期间成功完成天津、石家庄等地营销服务部的开设，以及友邦四川分公司的筹建工作。 南方财经全媒体记者 孙诗卉 此前，友邦人寿曾对21世纪经济报道记者透露，友邦未来的区域拓展计划以每年新增1-2家省级分支机 构的节奏进行，并设定了2025至2030年间新市场新业务价值复合年增长率达到40%的目标。 近日，21世纪经济报道记者从业内获悉，自2025年10月1日起，友邦人寿姜利民卸任副总经理兼广东分 公司总经理职务；副总经理兼深圳分公司总经理刘兴科将补位广东分公司总经理；同时湖北分公司总经 理叶刚将出任深圳分公司总经理。 2025年2季度末，友邦人寿综合偿付能力充足率410.03%，核心偿付能力充足率287.82%，风险综合评级 连续两个季度保持AAA。友邦2025年上半年年报数据显示，四川、湖北、河南、河北、天津、安徽、 山东、重庆、浙江9家机构新业务价值合计达6,100万美元，占友邦人寿新业务价值的8%。 业内人士指出，姜利民的 ...

Group 1 - The core viewpoint of the articles indicates that Luyuan Pharmaceutical's revenue has surpassed 20 billion yuan for the first time, reaching 20.471 billion yuan in 2024, with a year-on-year growth of 3.15%, while the net profit attributable to shareholders has declined by 4.92% to 346 million yuan, marking the first negative growth in recent years [2] - From the first quarter of 2024, Luyuan Pharmaceutical's quarterly profits have consistently declined, dropping from a growth of 4.9% to a decline of 14.86% in the first quarter of 2025 [2] - The pharmaceutical wholesale business accounted for 90.8% of total revenue in 2024, but its growth rate was only 1.85%, which negatively impacted overall performance; in contrast, the pharmaceutical retail and industrial businesses maintained double-digit growth rates of 14.46% and 25.16%, respectively, but their revenue contributions were insufficient to reverse the downturn [2] Group 2 - Luyuan Pharmaceutical's business heavily relies on a pure sales model, directly supplying to public hospitals at the secondary level and above, which, while securing quality clients, has led to a continuous rise in accounts receivable [2] - As of the end of 2024, the accounts receivable value was 5.902 billion yuan, accounting for 46.7% of total assets, and by the end of the first quarter of 2025, it further increased to 6.258 billion yuan, approaching 50% [2] - The high accounts receivable directly affects cash flow, with Luyuan Pharmaceutical's net cash flow from operating activities dropping by 55.89% to 577 million yuan in 2024, and a net outflow of 81 million yuan in the first quarter of 2025, although this was a narrowing year-on-year [2] Group 3 - In recent years, Luyuan Pharmaceutical has implemented a "going out of Fujian" strategy through acquisitions, achieving over 96% coverage of secondary hospitals in Sichuan, Jiangxi, and Hainan provinces; however, the effectiveness of regional expansion has varied significantly [3] - In 2024, the revenue contribution from Fujian province was 70.47%, with a growth rate of only 2.19%, nearly stagnant; Sichuan province contributed 16.45% with a year-on-year growth of 10.24%, while Jiangxi province accounted for 9.78% with a decline of 0.81% [3] - Future growth for Luyuan Pharmaceutical will likely depend on seeking development opportunities outside of its home province [3]